Anti-Cd22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-09-2980
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Preclinical and Clinical Evaluation of Epratuzumab (Anti-Cd22 IgG) in B-Cell Malignancies

Oncogene
Cancer ResearchGeneticsMolecular Biology
2007English

Liver Complications Following Treatment of Hematologic Malignancy With Anti-Cd22-Calicheamicin (Inotuzumab Ozogamicin)

Hepatology
MedicineHepatology
2019English

CAT-8015: A Second-Generation Pseudomonas Exotoxin A-Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies

Clinical Cancer Research
Cancer ResearchOncology
2009English

Design, Development, Characterization and Testing of CD22 Targeted Long Circulating Liposomal Drug Delivery Systems for B Cell Malignancies

English

N-Linked Glycosylation Regulates CD22 Organization and Function

Frontiers in Immunology
AllergyImmunology
2019English

Efficacy of an Anti-Cd22 Antibody-Monomethyl Auristatin E Conjugate in a Preclinical Xenograft Model of Precursor B-Cell Acute Lymphoblastic Leukemia

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2016English

Identification of CD22 Ligands on Bone Marrow Sinusoidal Endothelium Implicated in CD22-dependent Homing of Recirculating B Cells

Journal of Experimental Medicine
MedicineAllergyImmunology
1999English

Isolation of Anti-Cd22 Fv With High Affinity by Fv Display on Human Cells

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2006English

Hematologic Malignancies

Oncologist
Cancer ResearchMedicineOncology
1999English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy